4826406
Last Update Posted: 2021-04-01
Recruiting status is unknown
All Genders accepted | 18 Years + |
40 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).
The purpose of this study is to observe and preliminary explore the efficacy and safety of the combination of Camrelizumab and Apatinib regimen in treating advanced hepatocellular carcinoma (HCC) participants who have progressed following prior Immune Checkpoint Inhibitors (ICIs) treatment.
Eligibility
Relevant conditions:
Hepatocellular Carcinoma
Immune Checkpoint Inhibitors
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Shanzhi Gu, MD
gushanzhi@hnca.org.cn
+86-731-88651900
Data sourced from ClinicalTrials.gov